- The initiation of a clinical trial evaluating the rVSV-EBOV (Ebola) vaccine triggers a $20M milestone payment from Merck (NYSE:MRK) to NewLink Genetics (NASDAQ:NLNK).
- The rVSV-EBOV vaccine candidate, originally developed by the Public Health Agency of Canada, was licensed by NewLInk subsidiary BioProtection Systems. It was exclusively licensed to Merck on November 24, 2014.
NewLink earns $20M milestone from Merck for Ebola vaccine candidate
Recommended For You
More Trending News
About MRK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MRK | - | - |
Merck & Co., Inc. |